子宫肌瘤非子宫切除术治疗知情同意中讨论肉瘤风险:一个未被满足的需求
本文指出,在没有手术标本的情况下无法可靠区分症状性子宫肌瘤与肉瘤,许多子宫肉瘤患者最初在 presumed 肌瘤诊断下接受非子宫切除术治疗,却未了解肉瘤风险。 presumed 肌瘤女性中肉瘤发生率为0.29%(1/340)至0.05%(1/2000),非转移性平滑肌肉瘤5年生存率为63%,转移性平滑肌肉瘤5年生存率为14%。作者认为选择非子宫切除术的肌瘤女性应接受包含子宫肉瘤发生率和死亡率讨论的知情同意,且需研究如何以更少偏倚的方式提供肉瘤风险信息。
要点
- 无手术标本时无法可靠区分症状性子宫肌瘤与肉瘤。
- presumed 肌瘤女性肉瘤发生率为0.29%(1/340)至0.05%(1/2000)。
- 非转移性平滑肌肉瘤5年生存率63%,转移性平滑肌肉瘤5年生存率14%。
核心结论
- 选择非子宫切除术治疗肌瘤的女性应接受知情同意过程,其中特别包括讨论子宫肉瘤的发生率和死亡率。
- 对于许多有症状的肌瘤女性, presumed 肌瘤的非子宫切除术替代方案仍是可 preferable 的治疗选择,只要充分讨论了潜在的肉瘤风险。
- 研究需要确定如何在知情同意期间以更少偏倚的方式提供肉瘤风险信息。
研究设计与样本
- 本文为综述/观点类文章,检索范围未报告。
主要发现
- 在没有手术标本的情况下,没有可靠方法区分症状性子宫肌瘤与肉瘤。
- 许多子宫肉瘤女性最初在 presumed 肌瘤诊断下接受非子宫切除术治疗,而不了解肉瘤风险。
- presumed 肌瘤女性中肉瘤发生率为0.29%(1/340)至0.05%(1/2000)。
- 非转移性平滑肌肉瘤5年生存率为63%,转移性平滑肌肉瘤5年生存率为14%。
- 在子宫肉瘤中,常常在做出可能剥夺治愈机会的延迟手术决定之前无法识别谁有肉瘤。
关键数值与推荐
- presumed 肌瘤女性中肉瘤发生率为0.29%(1/340)至0.05%(1/2000)。
- 非转移性平滑肌肉瘤5年生存率为63%,转移性平滑肌肉瘤5年生存率为14%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 如何向患者呈现肉瘤风险信息以避免轻视肉瘤或惊吓女性转向子宫切除术尚未被研究。
- 需要研究确定如何在知情同意期间以更少偏倚的方式提供肉瘤风险信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is no reliable way to distinguish symptomatic uterine fibroids from sarcoma without a surgical specimen. Many women with a uterine sarcoma are initially managed without hysterectomy under a presumed fibroid diagnosis, without understanding sarcoma risks. Currently many alternatives to hysterectomy, including medical and procedural interventions, for treatment of fibroids are promoted. The sarcoma incidence among women with presumed fibroids is 0.29% (1/340) to 0.05% (1/2000). Nonmetastatic leiomyosarcoma has a 63% 5-year survival rate whereas metastatic leiomyosarcoma has a 14% 5-year survival rate. In uterine sarcoma, we often cannot identify who has sarcoma before making a potentially cure-denying decision by delaying surgery. Therefore, women electing an alternative to hysterectomy for fibroids should undergo an informed consent process that specifically includes discussion of uterine sarcoma incidence and mortality. Alternatives to hysterectomy for presumed fibroids remain preferable treatment options for many women with symptomatic fibroids, so long as underlying sarcoma risks are adequately discussed. The challenge for obstetrician- gynecologists then is how to provide better informed consent and maintain the primacy of patient autonomy over our concern to "First, do no harm." Major threats to patient's autonomy are faced in the sarcoma risk discussion. How we should present sarcoma risk information to avoid being dismissive of sarcoma or frightening women toward hysterectomy is unstudied. Research is needed to determine how to provide sarcoma risk information with less bias during informed consent.
引用
- Seagle BL, Alexander AL, Strohl AE, et al. Discussing sarcoma risks during informed consent for nonhysterectomy management of fibroids: an unmet need. Am J Obstet Gynecol. 2017. PMID: 28951264. doi:10.1016/j.ajog.2017.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。